StockData

CareDx vs GeneDx

CDNA and WGS side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CDNA and WGS compare

CareDx is the larger company, worth 2.6 times as much as GeneDx ($4.1B against $1.5B).

CareDx grew revenue faster over the last twelve months (38.9% versus 14.6% for GeneDx).

CareDx keeps more of each dollar of sales as profit, with a net margin of 25.9% compared with −24.1% at GeneDx.

CareDx scores higher on the StockData Score (12 against 3 for GeneDx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCDNAWGS
Size and price
Market cap$4.1B$1.5B
Share price$77.88$51.87
Change, 1 year377%−62.9%
Change, 5 years81.1%−78.4%
Beta (5Y)1.511.99
Employees7651,300
StockData Score
Total score12 (better)3
Valuation score00
Growth score2 (better)1
Performance score4 (better)1
Health score6 (better)1
Dividend score00
Valuation
P/E32.6×–
P/S8.2×3.4× (better)
P/B8.8×6.3× (better)
EV/EBITDA28.6×–
FCF yield–−6.5%
Fair value$58.77$32.27
Margin of safety−32.5% (better)−60.7%
Growth
Revenue growth (TTM)38.9% (better)14.6%
Revenue growth, 5Y average14.6%19.0% (better)
Net income growth (TTM)82.6% (better)−5431%
EPS growth (TTM)–−6400%
Profitability
Gross margin–68.7%
Operating margin23.4% (better)−21.6%
Net margin25.9% (better)−24.1%
FCF margin–−22.0%
Return on equity33.0% (better)−41.4%
Return on invested capital69.8% (better)−38.4%
Financial health
Debt / equity0.000.60 (better)
Current ratio2.314.16 (better)
Altman Z-score14.77 (better)0.16
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%107%
Held by insiders4.8%–
Insider net buying, 12 months−$18.4M$91.2M (better)
Short interest, % of float14.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.